Maggie L. Shaw

David J. Maron, MD, FASPC, president-elect of the American Society for Preventive Cardiology (ASPC), previews hot topics of interest at this year's congress and how lessons he has learned from current ASPC president Michael Shapiro, DO, FASPC, will shape his presidency set to commence next year.

At the 2025 Society for Pediatric Dermatology conference, Karen Vo, DO, presented research analyzing popular TikTok videos about epidermolysis bullosa, highlighting the platform’s power in raising awareness through emotional storytelling, and used her findings to advocate for early school-based mental health support and stronger, more inclusive antibullying policies for children with chronic skin conditions.

At the Society for Pediatric Dermatology Annual Meeting, Sarah Coates, MD, FAAD, highlights how social drivers shape pediatric skin health and how clinicians can respond.

Two posters presented at the Society for Pediatric Dermatology's Annual Meeting explore the psychological toll and potential nutritional approaches for managing vitiligo in children and adolescents.

Cory Simpson, MD, PhD, assistant professor of dermatology at the University of Washington, spoke to the need for more treatment options in genetic skin conditions and the possibility of drug repurposing.

The AllergyAware e-learning course effectively trained school personnel on anaphylaxis management, significantly improving their knowledge and confidence in using epinephrine auto-injectors, despite some technical and pacing issues reported by users.

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

At the recent regional Institute for Value-Based Medicine® event in Boston, Anasuya Gunturi, MD, PhD, Lowell General Hospital, was a panelist for the discussion, “Evolving Breast Cancer Care: Addressing Unmet Needs Across the Patient Journey.”

World Hepatitis Day 2025 and its theme, “Hepatitis: Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate hepatitis by 2030.

At the 6-month anniversary of the inauguration in January, The American Journal of Managed Care® looks back at the changes made by the Trump administration that could have lasting effects in health care.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer treatment continuum.

State governments must have budgetary and regulatory flexibility to support health care innovation, says State Sen Vincent Polistina (R, New Jersey).

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are contraindicated stand to benefit the most from this approval.

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice and looks to the future of treatment for the autoimmune neuromuscular disorder.

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies

Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely administer and manage them.

A new study shows low rates of pre-exposure prophylaxis (PrEP) prescribing to sexual and gender minority individuals living in North Carolina, indicating barriers like stigma and a misperception of risk as reasons for not using PrEP.

Ayodeji Adegunsoye, MD, PhD, MSc, discusses how emerging genetic insights like telomere-related mutations may reshape disease management in idiopathic pulmonary fibrosis (IPF).

Mental health, care of acute and chronic conditions, primary care access and prevention, and maternal and perinatal health were identified as key focus areas among a majority of states.

Investigators sought to measure and attribute out-of-pocket costs to cancer stage and by diagnosis.

Fewer than half of eligible patients with advanced ovarian cancer receive first-line maintenance treatments, highlighting care gaps.

According to the American Medical Association, blame for the ongoing physician shortage may lie with overly burdensome administrative processes, an antiquated Medicare payment system, and lack of education for residents in primary care and psychiatry.

The Society for Pediatric Dermatology’s 50th Annual Meeting will highlight advances in pediatric skin, hair, and nail care, with expert-led sessions on cutting-edge research and therapies.

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® produced over the first half of 2025. Give them all another listen, and perhaps learn something new.

Karen Fernandez, MD, discusses the different types of treatment currently being tested for use in dry eye disease, which affects millions in the US.

States participating in the Cell and Gene Therapy (CGT) Access Model will be testing outcomes-based payments for sickle cell disease treatments.